DUBLIN, Sept. 19, 2017 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH) announced today that members of
management will present a corporate overview at the Cantor
Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET. The conference will be held
September 25 - 27 at the
Intercontinental New York Barclay Hotel.
A live broadcast will be available by visiting the Investor
Relations section of Theravance Biopharma's website at
www.theravance.com, under the Presentations & Events tab.
Listeners are encouraged to visit the site at least 15 minutes
prior to the scheduled presentation to register, download and
install any necessary audio software.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical
company with the core purpose of creating medicines that help
improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates
includes potential best-in-class medicines to address the unmet
needs of patients being treated for serious conditions primarily in
the acute care setting. VIBATIV® (telavancin), our first
commercial product, is a once-daily dual-mechanism antibiotic
approved in the U.S., Europe and
certain other countries for certain difficult-to-treat infections.
Revefenacin (TD-4208) is a long-acting muscarinic antagonist
("LAMA") being developed as a potential once-daily, nebulized
treatment for chronic obstructive pulmonary disease ("COPD"). Our
neprilysin ("NEP") inhibitor program is designed to develop
selective NEP inhibitors for the treatment of a range of major
cardiovascular and renal diseases, including acute and chronic
heart failure, hypertension and chronic kidney diseases such as
diabetic nephropathy. Our research efforts are focused in the areas
of inflammation and immunology, with the goal of designing
medicines that provide targeted drug delivery to tissues in the
lung and gastrointestinal tract in order to maximize patient
benefit and minimize risk. The first program to emerge from this
research is designed to develop intestinally restricted pan-Janus
kinase ("JAK") inhibitors for the treatment of a range of
inflammatory intestinal diseases.
In addition, we have an economic interest in future payments
that may be made by Glaxo Group Limited or one of its affiliates
(GSK) pursuant to its agreements with Innoviva, Inc. relating to
certain drug development programs, including Trelegy Ellipta (the
combination of fluticasone furoate, umeclidinium, and vilanterol in
a single ELLIPTA® inhaler, previously referred to as the
Closed Triple), currently approved in the US for the treatment of
appropriate COPD patients and in development for the treatment of
COPD in several other countries. The product is also currently in
development for the treatment of asthma.
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and
VIBATIV® are registered trademarks of the Theravance
Biopharma group of companies.
Contact Information:
Alexander Dobbin
Head of Investor Relations
650-808-4045
investor.relations@theravance.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300521289.html
SOURCE Theravance Biopharma, Inc.